Related references
Note: Only part of the references are listed.Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma
Daniele Caracciolo et al.
HAEMATOLOGICA (2021)
LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia
Zhou Yu et al.
THERANOSTICS (2021)
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Hyoung Kim et al.
NATURE COMMUNICATIONS (2020)
Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3-and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia
Yue Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
Domenica Lorusso et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma
J. R. Nair et al.
LEUKEMIA (2017)
EXPRESSION OF PIM KINASES IN REED-STERNBERG CELLS FOSTERS IMMUNE PRIVILEGE AND TUMOR CELL SURVIVAL IN HODGKIN LYMPHOMA
M. Szydlowski et al.
HEMATOLOGICAL ONCOLOGY (2017)
Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells
Jia Qu et al.
JOURNAL OF CELL BIOLOGY (2017)
Targeting Ongoing Dna Damage in Multiple Myeloma: effects of Dna Damage response inhibitors on Plasma cell survival
Ana Belen Herrero et al.
FRONTIERS IN ONCOLOGY (2017)
Cell cycle proteins as promising targets in cancer therapy
Tobias Otto et al.
NATURE REVIEWS CANCER (2017)
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
Per Hydbring et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
Pim2 is important for regulating DNA damage response in multiple myeloma cells
J. Ramachandran et al.
BLOOD CANCER JOURNAL (2016)
Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma
Antonia Cagnetta et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma
M. Hiasa et al.
LEUKEMIA (2015)
Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation
Jing Lu et al.
BLOOD (2013)
Betulinic acid inhibits autophagic flux and induces apoptosis in human multiple myeloma cells in vitro
Li-jing Yang et al.
ACTA PHARMACOLOGICA SINICA (2012)
Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX
D. K. Walters et al.
LEUKEMIA (2011)
The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells
J. Asano et al.
LEUKEMIA (2011)
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers
Laurent Brault et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Pim-2 Activates API-5 to Inhibit the Apoptosis of Hepatocellular Carcinoma Cells Through NF-κB Pathway
Ke Ren et al.
PATHOLOGY & ONCOLOGY RESEARCH (2010)
Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery
Libor Macurek et al.
NATURE (2008)
Bora and the kinase Aurora A cooperatively activate the kinase Plk1 and control mitotic entry
Akiko Seki et al.
SCIENCE (2008)
Pim-I expression in prostatic intraepithelial neoplasia and human prostate cancer
A Valdman et al.
PROSTATE (2004)
The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death
B Yan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
T Hirano et al.
ONCOGENE (2000)
Share Paper
